Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R. Mirza, Ursula A. Matulonis, Domenica Lorusso et al.|New England Journal of Medicine|2016Cited by 2.5k
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, Dominique Berton et al.|JAMA Network Open|2023Cited by 120
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET StudyAna Oaknin, Anna V. Tinker, Bhavana Pothuri et al.|Clinical Cancer Research|2023Cited by 80
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Kathleen N. Moore, Toon Van Gorp, Antoine Angelergues et al.|Journal of Clinical Oncology|2023Cited by 53